Neurodegenerative diseases

ELND005, an Aß aggregation inhibitor

The small molecule ELND005 is a beta amyloid anti-aggregation agent that also has been granted fast track designation by the FDA. In December 2007, Elan and Transition announced that the first patient had been dosed in a Phase 2 clinical study. This 18-month, randomized, double-blind, placebo-controlled, dose-ranging study is evaluating the safety and efficacy of ELND005 in patients with mild to moderate Alzheimer’s disease. In October 2008, Elan and Transition announced that the patient enrollment target for this study had been achieved with 353 patients enrolled. In December 2009, Elan and Transition announced that patients would be withdrawn from the two higher dose cohorts due to safety concerns. The study is continuing for the lower dose group.

Alzheimer's Immunotherapy Program (Bapineuzumab, AAB002, ACC-001)

In September 2009, JANSSEN Alzheimer Immunotherapy, a subsidiary of Johnson & Johnson, acquired substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP), including bapineuzumab. 
 
For information about AIP, including clinical trials, please contact:

JANSSEN Alzheimer Immunotherapy (Dublin)
Treasury Building
Lower Grand Canal Street
Dublin 2, Ireland
Telephone: +353.1.709.4900
Fax: +353.1.709.4950
 
JANSSEN Alzheimer Immunotherapy Research & Development, LLC (South San Francisco)
700 Gateway Blvd
South San Francisco, CA 94080
Telephone: +1 650.794.2500; +1 888.381.4595